Original Research

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

He YY, Liu ST, Mattei J, Bunn Jr PA, Zhou CC, Chan D

Drug Design, Development and Therapy 2018, 12:981-986

Published Date: 24 April 2018